Gentle treatment tested for dangerous blood disorder
NCT ID NCT04754945
Summary
This early-stage study is testing a new, cautious treatment strategy for patients with high-risk AL amyloidosis, a serious disease where abnormal proteins damage organs. Doctors are slowly adding different drugs, starting with isatuximab, to find the most effective combination patients can tolerate. The main goal is to see if this 'slow-go' method is safe and can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10032, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 39322, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
-
University of California
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.